Dr. Devi warns slow titration cuts brain bleed risk

Sunday, July 19, 2026 · from 2 podcasts

Standard dosing for new Alzheimer’s drugs risks brain bleeds in high-risk patients.
Ultra-slow titration slashes ARIA rates from 40% to 4%, data shows.
Insurance won’t cover safer off-label protocols, forcing patients to pay out of pocket.

Standard dosing schedules for anti-amyloid drugs are inviting preventable brain hemorrhages, according to Dr. Gayatri Devi on The Peter Attia Drive. The risk is highest for APOE4 homozygotes - patients with two copies of the gene - who are also the most likely to benefit from early intervention. Yet FDA-approved titration protocols move too fast for these vulnerable patients.

Devi implements a personalized, ultra-slow ramp-up in her practice. While clinical trials reported ARIA - amyloid-related imaging abnormalities - in up to 40% of high-risk patients, her adjusted protocol reduced the incidence to roughly 4%. She argues the trade-off between 18-month and 24-month plaque clearance is irrelevant if the patient suffers a catastrophic bleed.

"We’re trading a small delay in amyloid clearance for a massive reduction in brain hemorrhage risk. For APOE4 homozygotes, that’s not just conservative - it’s essential."
- Dr. Gayatri Devi, The Peter Attia Drive

Insurance companies block access to these safer regimens. They routinely deny reimbursement for off-label titration schedules, leaving patients to choose between standard dosing or self-funding a safer path. This creates a two-tier system: those who can pay get protection; others face preventable risk.

The challenge extends beyond dosing. Devi emphasizes that Alzheimer’s is not a single entity but a spectrum with comorbid pathologies. Amyloid is just one marker - present in 25% of people in their 70s and 44% by age 90 - often without symptoms. Relying on blood tests alone risks misdiagnosing hormone-related cognitive decline as dementia.

"The brain doesn’t care about our diagnostic categories. It cares about inflammation, vascular health, and synaptic function. We have to treat the system, not the label."
- Dr. Gayatri Devi, The Peter Attia Drive

Menopause-related cognitive impairment mimics early Alzheimer’s. Devi has reversed 'pseudo-dementia' in patients with hormone replacement therapy - highlighting a lost generation of women denied HRT after the 2002 Women’s Health Initiative. For these patients, estrogen withdrawal may have accelerated cognitive decline.

2 Sources:

Hidden Brain Peter Attia Drive

#Mental Health #Health #Biology

Source Intelligence

- Deep dive into what was said in the episodes

Hidden Brain

Changing Our Mental Maps • Jul 13

Also from this episode: (17)

Psychology (16)

Norman Farb says the default mode network automates patterns in life, making our brain a prediction machine that prioritizes efficiency over effortful processing.
Farb identifies a neural trade-off: the default mode network’s efficiency creates massive blind spots to possibilities outside our learned habits, hindering our ability to change.
Norman Farb’s neuroimaging study found depression was linked to deactivation of brain regions that process bodily sensations, not increased activity in the default mode network.
Farg argues that suppressing bodily sensations during sadness creates a feedback loop: the brain ruminates without new sensory input, perpetuating the negative state.
Norman Farb describes a tale of two brain partners: the front brain’s model-making network versus the back brain’s sensory regions open to chaotic, changing reality.
Farb says stress makes us rely on known mental tools, even if those tools are the source of our recurring conflicts or despair, trapping us in harmful patterns.
Reliving a stressful event mentally can trigger the body’s stress response anew, effectively re-inflicting the trauma long after the actual event has ended.
Norman Farb connects the Buddha's parable of the second arrow to modern psychology: the stories we tell about negative events are the arrows we plunge into old wounds.
Farb argues feeling disconnected from others often stems from prioritizing our internal model of being 'right' over the sensory feeling of connection during interactions.
Norman Farb uses a tactile morning ritual - feeling cold bathroom tiles - to break through his grumpy mental model and remind himself to be intentional in his relationships.
When frustrated with his kids being late, Farb shifted from an angry model of lecturing to a playful model of connection, becoming a 'tickle monster' to get them moving.
Farg concludes that reconnecting with sensation is the start of exploration, allowing us to find solutions outside our expected models if we are willing to be surprised.
Norman Farb’s mother, Linda, internalized a map from her Holocaust-survivor parents: being a good girl, wife, and mother would guarantee security and stability.
Linda’s divorce catastrophically violated her life map, leading to deep depression where she ruminated on past hurts despite intellectually understanding it caused suffering.
Farb initially had a map of being the helpful son who could fix his mother through psychological reasoning, which led to frustration and resentment when it failed.
Farb broke the script by accepting he could not fix his mother, shifting conversations to small talk and present connection, which shortened calls and improved their relationship.

AI & Tech (1)

The podcast illustrates the danger of faulty mental maps with a 2024 incident where German tourists in Queensland followed Google Maps onto a mud-trapped dirt track, getting stuck for days.

#Psychology #Brain #Mental Health

The Peter Attia Drive

#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D. • Jul 13

Dr. Devi views dementia disorders like Alzheimer's, vascular, and Lewy body disease as a spectrum, not discrete entities. Most Alzheimer's patients have comorbid brain pathologies.
In Alzheimer's pathology, neuroinflammatory changes may precede amyloid deposition, which then triggers tau and synaptic dysfunction. Devi argues this cascade can be interrupted with early anti-inflammatory lifestyle interventions.
Dr. Devi's diagnostic protocol for high-functioning patients involves lengthy cognitive testing, transcranial Doppler, specialized MRI, amyloid/tau PET scans, DAT scans, and lab tests for APOE genotype and inflammatory markers. She critiques standardized blood tests for amyloid alone.
Amyloid prevalence rises with age: Devi cites community data showing amyloid in 25% of people in their 70s, 30+% in their 80s, and 44% by age 90, often without symptoms. She warns against diagnosing Alzheimer's solely on amyloid biomarkers.
Two copies of the APOE4 allele increase Alzheimer's risk by 60% relative to the wild type. Devi compares this risk level to a BRCA gene for breast cancer.
In clinical trials, anti-amyloid drugs show small benefits: Devi cites CDR-SB score improvements of 0.3-0.4 points out of 18. She argues early intervention before significant tau pathology yields greater benefit.

Also from this episode: (7)

Health (4)

Devi links women's higher Alzheimer's prevalence to longer post-menopause estrogen deprivation, greater survival post-cardiovascular events, and immunological differences. She notes women often present with depression and language issues, while men show aggression.
Menopause-related cognitive impairment can mimic early Alzheimer's symptoms. Devi has treated this successfully with hormone replacement, cholinesterase inhibitors, and targeted brain exercises.
Dr. Devi developed a slow titration protocol for anti-amyloid monoclonal antibodies to reduce ARIA side effects. In her 4/4 APOE patients, this lowered ARIA incidence to 4%, with only one symptomatic case over five years.
Leqembi and Kisunla are priced at ~$26,000 annually for the drug, plus administration fees ranging from $400 to $10,000 per infusion. Devi notes insurers often reject reimbursement for her slower titration protocol.

Mental Health (3)

Devi's multimodal treatment for dementia includes cholinesterase inhibitors, memantine, valacyclovir for some, immune-modifying drugs, VP shunt for hydrocephalus, and off-label transcranial magnetic stimulation to maintain neuronal connectivity.
Lewy body dementia often coexists with Alzheimer's pathology: autopsy studies show 40% of Alzheimer's patients have Lewy body pathology, and ~30-40% of Lewy body patients have Alzheimer's pathology.
Devi distinguishes Lewy body dementia from Parkinson's by noting Lewy body patients rarely have a classic pill-rolling tremor and often retain insight into their visual hallucinations.

#Longevity #Health #Biology #Psychology